GENE ONLINE|News &
Opinion
Blog

2021-07-04| M&A

EQT Private Equity and Goldman Sachs Spend $8.5 Billion to Acquire Parexel

by Daniel Ojeda
Share To
On July 2nd, EQT Private Equity, a Swedish firm part of EQT AB, announced it would team up with Goldman Sachs to acquire Parexel, a clinical research organization (CRO). They would buy it from its current owner Pamplona Capital Management for $8.5 billion. The announcement comes amid EQT Private Equity’s restructuring of its healthcare-related holdings.  

GO Prime with only $1.49 now

LATEST
Healthcare Through the Eyes of AI: Coding the Future of Medicine Through Digital Acceleration
2025-03-21
European Pharmaceutical Review Highlights RNA Therapeutics and Process Analytical Technology in 2025 Issue 1
2025-03-21
Study Examines Long-Term Effects of Anti-Amyloid Drug for Rare Alzheimer’s Variant
2025-03-21
Sanofi Acquires Bispecific Drug Candidate in $600 Million Deal Focused on Autoimmune Disorders
2025-03-21
Trump Administration Policies May Impact Health Care for Intersex Individuals
2025-03-21
Federal Health Care Research Agency Faces Potential Mass Layoffs
2025-03-21
Police and Hospitals’ Drug Confiscation Practices Examined
2025-03-21
EVENT
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
Scroll to Top